Literature DB >> 8839858

Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes.

S D Mundle1, P Venugopal, J D Cartlidge, D V Pandav, L Broady-Robinson, S Gezer, E L Robin, S R Rifkin, M Klein, D E Alston, B M Hernandez, D Rosi, S Alvi, V T Shetty, S A Gregory, A Raza.   

Abstract

Our previous studies using in situ end labeling (ISEL) of fragmented DNA revealed extensive apoptotic cell death in the bone marrows (BM) of patients with myelodysplastic syndromes (MDS) involving both stromal and hematopoietic cells. In the present report we show greater synthesis of interleukin-1 beta (IL-1 beta) in 4 hour cultures of density separated BM aspirate mononuclear (BMAM) cells from MDS patients as compared to the cultures of normal BM from healthy donors or lymphoma patients (1.7 +/- 0.37 pg/10(5) cells, n = 29 v 0.42 +/- 0.24 pg/10(5) cells, n = 11, respectively, P = .049). Further, these amounts of IL-1 beta in MDS showed a significant correlation with the extent of apoptosis detected by ISEL in corresponding plastic embedded BM biopsies (r = .480, n = 30, P = .007). In contrast normal BMs did not show any correlation between the two (r = .091, n = 12, P = .779). No significant correlation was found between the amounts of IL-1 beta and % S-phase cells (labeling index; LI%) in MDS determined in BM biopsies using immunohistochemistry following in vivo infusions of iodo- and/or bromodeoxyuridine. Neither anti-IL-1 beta antibody nor IL-1 receptor antagonist blocked the apoptotic death of BMAM cells in 4 hour cultures (n = 5) determined by ISEL (apoptotic index; AI%), although the latter led to a dose-dependent accumulation of active IL-1 beta in the culture supernatants. On the other hand, a specific tetrapetide-aldehyde inhibitor of ICE significantly retarded the apoptotic death of BMAM cells at 1 mumol/L in 5/6 MDS cases studied (AI% = 2.99 +/- 0.30 in controls v 1.58 +/- 0.40 with ICE-inhibitor, P = .05) and also reduced the levels of active IL-1 beta synthesized (5.59 +/- 2.63 v 2.24 +/- 0.93 pg/10(6) cells, respectively). In normal cells, neither IL-1 blockers nor the ICE inhibitor showed any effect on the marginal increase in apoptosis observed in 4 hour cultures. Our data thus suggest a possible involvement of an ICE-like protease in the intramedullary apoptotic cell death in the BMs of MDS patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8839858

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Apoptosis in haematological malignancies.

Authors:  J A DiGiuseppe; M B Kastan
Journal:  J Clin Pathol       Date:  1997-05       Impact factor: 3.411

2.  The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype.

Authors:  Ashley A Basiorka; Kathy L McGraw; Erika A Eksioglu; Xianghong Chen; Joseph Johnson; Ling Zhang; Qing Zhang; Brittany A Irvine; Thomas Cluzeau; David A Sallman; Eric Padron; Rami Komrokji; Lubomir Sokol; Rebecca C Coll; Avril A B Robertson; Matthew A Cooper; John L Cleveland; Luke A O'Neill; Sheng Wei; Alan F List
Journal:  Blood       Date:  2016-10-13       Impact factor: 22.113

Review 3.  Infections in myelodysplastic syndromes.

Authors:  Andréa Toma; Pierre Fenaux; François Dreyfus; Catherine Cordonnier
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

Review 4.  The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression.

Authors:  Allison J Li; Laura M Calvi
Journal:  Exp Hematol       Date:  2017-08-18       Impact factor: 3.084

5.  Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome.

Authors:  Krishnan Allampallam; Vilasini Shetty; Suneel Mundle; Diya Dutt; Howard Kravitz; Poluru L Reddy; Sairah Alvi; Naomi Galili; Gurveen S Saberwal; Shalini Anthwal; Maliha W Shaikh; Aaron York; Azra Raza
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

6.  The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes.

Authors:  Xiang Li; A Mario Marcondes; Theodore A Gooley; H Joachim Deeg
Journal:  Blood       Date:  2010-06-18       Impact factor: 22.113

Review 7.  Genetics of progression from MDS to secondary leukemia.

Authors:  Andrew J Menssen; Matthew J Walter
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

8.  Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes.

Authors:  Wendy W Pang; John V Pluvinage; Elizabeth A Price; Kunju Sridhar; Daniel A Arber; Peter L Greenberg; Stanley L Schrier; Christopher Y Park; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-06       Impact factor: 11.205

9.  NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs).

Authors:  Daniella M B Kerbauy; Vladimir Lesnikov; Nissa Abbasi; Sudeshna Seal; Bart Scott; H Joachim Deeg
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

10.  Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function.

Authors:  A Mario Marcondes; Andrew J Mhyre; Derek L Stirewalt; Soo-Hyun Kim; Charles A Dinarello; H Joachim Deeg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.